Last update July 12, 2023
Likely Compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Saquinavir (SQV) is also known as
Saquinavir (SQV) in other languages or writings:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 4 (1 - 9) | % |
Molecular weight | 671 | daltons |
Protein Binding | 98 | % |
VD | 10 | l/Kg |
pKa | 13.61 | - |
Tmax | 3 | hours |
T½ | 7 - 13 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by La Liga de la Leche, España of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Saquinavir is an inhibitor of HIV-1 and HIV-2 protease used in combination with other antiretroviral agents for the treatment of HIV infection with advanced immunodeficiency. Oral administration twice a day.
At the date of the last update we did not find any published data on its excretion in breast milk.
Its pharmacokinetic characteristics (moderately elevated molecular weight, high plasma protein binding and large volume of distribution) make it very unlikely its excretion into breast milk in significant amounts.
Its very low oral bioavailability minimizes the passage into plasma of the infant from ingested breast milk, except in the premature and in the immediate neonatal period in which there may be greater intestinal permeability.
One of these antiretroviral treatment (ART) regimens is recommended for nursing mothers diagnosed with acute HIV infection (Panel USA 2022):
"Individuals with HIV who are on ART with a sustained undetectable viral load and who choose to breastfeed should be supported in this decision". (Panel 2022 p ix)
See below the information of this related product: